Mela Aneta, Rdzanek Elżbieta, Poniatowski Łukasz A, Jaroszyński Janusz, Furtak-Niczyporuk Marzena, Gałązka-Sobotka Małgorzata, Olejniczak Dominik, Niewada Maciej, Staniszewska Anna
Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, Poland.
Department of Neurosurgery, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Front Pharmacol. 2020 Sep 8;11:1231. doi: 10.3389/fphar.2020.01231. eCollection 2020.
Cardiovascular diseases are associated with growing public and private expenditure on healthcare regardless geographic region. Therefore, it is necessary to accurately estimate the overall societal costs-both direct and indirect expenses from the perspective of patients, caregivers and employers.
The aim of this paper is to determine the direct and indirect costs related to cardiovascular diseases in Poland from 2015 to 2017. All costs are estimated based on data available in the public domain and obtained from the major Polish institutions. Indirect costs were calculated using a modified human capital approach.
The financial burden of cardiovascular diseases in Poland is significant. This study revealed that total costs (direct and indirect) of cardiovascular diseases, for 2015-2017, range from 34.9 bn PLN (8.2 bn EUR) to over 40.9 bn PLN (9.6 bn EUR). Total direct cost and indirect costs were approximately 6.1 bn PLN (1.4 bn EUR) (16%) and 31.3 bn PLN (7.3 bn EUR) (84%), respectively.
Collectively, the estimated direct and indirect cost of cardiovascular diseases provide a useful input for economic impact assessments of public health programs and health technology analyses.
无论地理区域如何,心血管疾病都与公共和私人医疗保健支出的增长相关。因此,有必要从患者、护理人员和雇主的角度准确估计总体社会成本,包括直接和间接费用。
本文旨在确定2015年至2017年波兰与心血管疾病相关的直接和间接成本。所有成本均根据公共领域可用的数据并从波兰主要机构获取的数据进行估算。间接成本采用改良的人力资本方法计算。
波兰心血管疾病的经济负担很重。该研究表明,2015年至2017年心血管疾病的总成本(直接和间接)从349亿波兰兹罗提(82亿欧元)到超过409亿波兰兹罗提(96亿欧元)不等。直接成本和间接成本总计分别约为61亿波兰兹罗提(14亿欧元)(16%)和313亿波兰兹罗提(73亿欧元)(84%)。
总体而言,心血管疾病的直接和间接成本估计为公共卫生项目的经济影响评估和卫生技术分析提供了有用的参考。